Analyst consensus rating
Rocket Pharmaceuticals Analyst Rating: Buy
Direct answer
Rocket Pharmaceuticals's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.84.
Forecast evidence checked September 12, 2026.
Get free Rocket Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.35
- Average price target
- $8.84
- High price target
- $15.00
- Low price target
- $3.00
- Low target gap
- -10.4%
- Target upside
- +163.9%
- High target gap
- +347.8%
- Target range width
- 358.2%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- September 12, 2026
- Valid through
- September 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rocket Pharmaceuticals?
Rocket Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $8.84.
How far are Rocket Pharmaceuticals's low and high targets from the recorded price?
The low target implies -10.4%, while the high target implies +347.8%.
How many analysts are included in Rocket Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is Rocket Pharmaceuticals's target upside or downside calculated?
The average target of $8.84 is divided by the recorded price of $3.35, then one is subtracted to produce +163.9%. This does not guarantee a future return.
When was Rocket Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-12. The dataset is valid through 2026-09-19.